Zgoo Holdings지구홀딩스

Zgoo Holdings is loss-making on a trailing basis, with its share price down sharply over three months and a recent CEO change.

Zgoo Holdings runs in vitro diagnostic testing services and medical IT software, collecting samples through one direct store and 19 agencies. On a trailing twelve-month basis to H1 2026, revenue was ₩32.1B with an operating loss of ₩3.6B and a net loss of ₩5.4B, and free cash flow was negative at ₩7.9B. The data does not include analyst forecasts or a fair value estimate.

What stands out

• Trailing revenue of ₩32.1B is above the 2025 full-year figure of ₩25.6B, but operating margin is -11.2% and net margin is -16.8%.
• Losses have persisted: operating losses in 2023, 2024 and 2025, with net income positive only in 2023 (₩0.6B).
• Cash of ₩10.1B against borrowings of ₩0.3B, though free cash flow of -₩7.9B on a trailing basis points to heavy cash use.
• Share price is ₩3,500, down 22.6% over three months and 3.3% over one month, versus a 52-week high of ₩32,800; the one-year return is 0.6%.
• Filings in 2026 include a CEO change (Aug 27), preliminary consolidated earnings (Aug 19), a rights offering decision (May 22) and amended half-year report (Oct 1); no news headlines were provided.

What to watch

• Next results and whether the loss narrows from the trailing H1 2026 level; the data does not give a forecast.
• Details of the rights offering (paid-in capital increase) and its effect on shares outstanding, which the data does not specify further.
• Foreign ownership fell from 3.8% to 2.2% over 60 days, and the new CEO's plans are not described in the data.